214 related articles for article (PubMed ID: 37391485)
1. RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia.
Marion W; Koppe T; Chen CC; Wang D; Frenis K; Fierstein S; Sensharma P; Aumais O; Peters M; Ruiz-Torres S; Chihanga T; Boettcher S; Shimamura A; Bauer DE; Schlaeger T; Wells SI; Ebert BL; Starczynowski D; da Rocha EL; Rowe RG
Leukemia; 2023 Aug; 37(8):1698-1708. PubMed ID: 37391485
[TBL] [Abstract][Full Text] [Related]
2. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
3. Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms.
Chao MM; Thomay K; Goehring G; Wlodarski M; Pastor V; Schlegelberger B; Schindler D; Kratz CP; Niemeyer C
Klin Padiatr; 2017 Nov; 229(6):329-334. PubMed ID: 29132164
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.
Quentin S; Cuccuini W; Ceccaldi R; Nibourel O; Pondarre C; Pagès MP; Vasquez N; Dubois d'Enghien C; Larghero J; Peffault de Latour R; Rocha V; Dalle JH; Schneider P; Michallet M; Michel G; Baruchel A; Sigaux F; Gluckman E; Leblanc T; Stoppa-Lyonnet D; Preudhomme C; Socié G; Soulier J
Blood; 2011 Apr; 117(15):e161-70. PubMed ID: 21325596
[TBL] [Abstract][Full Text] [Related]
5. Fanconi anemia and the development of leukemia.
Alter BP
Best Pract Res Clin Haematol; 2014; 27(3-4):214-21. PubMed ID: 25455269
[TBL] [Abstract][Full Text] [Related]
6. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
Venkatraj VS; Gaidano G; Auerbach AD
Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
[TBL] [Abstract][Full Text] [Related]
7. Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia.
Mehta PA; Harris RE; Davies SM; Kim MO; Mueller R; Lampkin B; Mo J; Myers K; Smolarek TA
Cancer Genet Cytogenet; 2010 Dec; 203(2):180-6. PubMed ID: 21156231
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
9. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
[TBL] [Abstract][Full Text] [Related]
10. Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: a view from the window of Fanconi anemia.
Lensch MW; Rathbun RK; Olson SB; Jones GR; Bagby GC
Leukemia; 1999 Nov; 13(11):1784-9. PubMed ID: 10557053
[TBL] [Abstract][Full Text] [Related]
11.
Olofsen PA; Touw IP
Mol Cells; 2020 Feb; 43(2):139-144. PubMed ID: 32041395
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow cell cycle markers in inherited bone marrow failure syndromes.
Al-Rahawan MM; Alter BP; Bryant BJ; Elghetany MT
Leuk Res; 2008 Dec; 32(12):1793-9. PubMed ID: 18606449
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia.
Savage SA; Walsh MF
Hematol Oncol Clin North Am; 2018 Aug; 32(4):657-668. PubMed ID: 30047418
[TBL] [Abstract][Full Text] [Related]
14. Fanconi Anemia patient with AML1 gene amplification and monosomy 7 in pre-transplant myelodysplasia (MDS) relapsing 7 years after successful allo-SCT.
Ayas M; Walter C
Bone Marrow Transplant; 2008 Oct; 42(8):555-7. PubMed ID: 18622412
[No Abstract] [Full Text] [Related]
15. A Systematic Review of the Role of Runt-Related Transcription Factor 1 (RUNX1) in the Pathogenesis of Hematological Malignancies in Patients With Inherited Bone Marrow Failure Syndromes.
Illango J; Sreekantan Nair A; Gor R; Wijeratne Fernando R; Malik M; Siddiqui NA; Hamid P
Cureus; 2022 May; 14(5):e25372. PubMed ID: 35765406
[TBL] [Abstract][Full Text] [Related]
16. Hereditary Predispositions to Myelodysplastic Syndrome.
Bannon SA; DiNardo CD
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27248996
[TBL] [Abstract][Full Text] [Related]
17. NK Cell Development and Function in Patients with Fanconi Anemia.
Hashemi E; Bjorgaard S; Wang D; Uyemura B; Riese M; Thakar MS; Malarkannan S
Crit Rev Immunol; 2021; 41(2):35-44. PubMed ID: 34348001
[TBL] [Abstract][Full Text] [Related]
18. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
19. How I treat MDS and AML in Fanconi anemia.
Peffault de Latour R; Soulier J
Blood; 2016 Jun; 127(24):2971-9. PubMed ID: 27020090
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
